Conexeu Sciences (CNXU) Stock Price, News & Analysis

Company Overview

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. --- Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property ("IP") developed over more than a decade at the University of British Columbia (the "University") and the BC Professional Firefighters Burn and Wound Healing Laboratory. In November 2023, the Company entered into a patent assignment agreement with the University pursuant to which the Company acquired an assignment of the University's right, title, and interest in the applicable patents and patent applications related to the underlying technology. The Company's only device candidate is the CXU™ scaffold device candidate, which is in preclinical development and has not been approved or cleared for marketing in any jurisdiction. The Company is conducting preclinical research and preparing for regulatory engagement to evaluate potential use in wound care and other medical applications. Any potential benefits to patients, providers, or healthcare systems have not been established and will require further study and regulatory review. CXU™ is a temperature-responsive, collagen-based extracellular matrix ("ECM") formulation designed to transition from a liquid to a gel-like scaffold following topical application or injection, typically within approximately ten minutes (the "10 Minute Tissue™" concept). The device IP is protected by issued and pending patents and is being evaluated in preclinical studies for its ability to provide an ECM-like environment associated with cellular infiltration, vascularization, and organized tissue remodeling in non-clinical models. We intend to seek U.S. Food and Drug Administration ("FDA") clearance in the United States for the CXU™ scaffold device candidate through the 510(k) premarket notification process as a Class II medical device; however, the FDA has not yet determined the appropriate classification or regulatory pathway for our device candidate, may require additional data or a different pathway, and there can be no assurance that we will obtain clearance or that the device candidate will become commercially available. Our principal executive offices are located in Reno, Nevada.

Key Stats

• Today's Range: $5.38 to $6.10
• 50-Day Range: $5.87 to $11.18
• 52-Week Range: $5.38 to $18.79
• Volume: 150,478 shs
• Average Volume: 151,145 shs
• Market Capitalization: $151.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.00
• Consensus Rating: Hold

Conexeu Sciences Stock Analysis - MarketRank™

Conexeu Sciences scored higher than 72% of companies evaluated by MarketBeat, and ranked 186th out of 916 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Conexeu Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Conexeu Sciences has a consensus price target of $20.00, representing about 239.7% upside from its current price of $5.89.

Amount of Analyst Coverage

Conexeu Sciences has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Conexeu Sciences are expected to decrease in the coming year, from ($0.40) to ($0.53) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Conexeu Sciences is -50.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Conexeu Sciences is -50.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.48% of the float of Conexeu Sciences has been sold short.

Short Interest Ratio / Days to Cover

Conexeu Sciences has a short interest ratio ("days to cover") of 0.81, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Conexeu Sciences has recently decreased by 12.40%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Conexeu Sciences does not currently pay a dividend.

Dividend Growth

Conexeu Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.16

News Sentiment

Conexeu Sciences has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Conexeu Sciences this week, compared to 3 articles on an average week.

Search Interest

Only 9 people have searched for CNXU on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

17 people have added Conexeu Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 70% compared to the previous 30 days.

Company Ownership

• Score: 2.9 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $162,000.00 in company stock, which represents 0.1028% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Conexeu Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $162,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Institutions

Conexeu Sciences has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 6/15/2026
• Today: 9/02/2026
• Fiscal Year End: 10/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:CNXU
• CIK: 2066836
• Web: www.conexeu.com
• Phone: (604) 315-4722
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Conexeu Sciences: $20.00
• High Price Target: $20.00
• Low Price Target: $20.00
• Potential Upside/Downside: +253.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.93
• Quick Ratio: 14.93

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 26,760,000
• Free Float: N/A
• Market Cap: $151.33 million
• Optionable: N/A
• Beta: N/A